Network Insights Methodology Get Access

Eli Lilly

PERSON Health Care / Pharmaceuticals Momentum 8.1 NORMAL Primary: Spectral Shift

$647B market cap (Indianapolis) Eli Lilly posted record Q4 2025 revenue driven by Zepbound and Mounjaro weight-loss drug sales surging 300%+ year-over-year. Company raised full-year guidance while aggressively deploying capital into cancer oncology acquisitions and AI-enabled gene editing partnerships.

$3.2B acquisition of struggling cancer startup; partnership with AI startup for next-generation gene editing technology
-0.61
PSI Score
8.1
Momentum
1%
Confidence
25
Connections
Connected Entities
NYSE Morgan Stanley FDA Novo Nordisk Nvidia United States Apple Bloomberg Alphabet Amazon Elon Musk Microsoft SEC SpaceX Tesla
Watch This Entity
PSI Intelligence
30-Day Trend
2026-04-07 2026-05-07 26 0 Degree Mentions
Signal Decomposition
Attention Cascade
-0.445
Narrative Drift
0.137
Spectral Shift
420.548
Sentiment-Momentum Divergence
0.000
Source Concentration
0.300
Network Analysis
25 Degree Centrality
Centrality History
2026-04-07 2026-05-07 26 0 Degree Mentions
EntityWeight StatusFirst Seen
NYSE 22 NEW
Morgan Stanley 18 NEW
FDA 8 NEW
Novo Nordisk 7 NEW
Nvidia 5 NEW
United States 5 NEW
Apple 4 NEW
Bloomberg 4 NEW
Alphabet 3 NEW
Amazon 3 NEW
Elon Musk 3 NEW
Microsoft 3 NEW
SEC 3 NEW
SpaceX 3 NEW
Tesla 3 NEW
Walmart 3 NEW
AstraZeneca 3 NEW
China 2 NEW
Hong Kong 2 NEW
Intel 2 NEW
Merck 2 NEW
CEO 2 NEW
M&A 2 NEW
Donald Trump 2 NEW
Jim Cramer 2 NEW
Article Coverage (0)
DateLaneTitle

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-05-07 ← Intelligence Network